Replicate Bioscience takes aim at mono-causing virus after promising results with mRNA rabies shot

Repli­cate Bio­science, a San Diego start­up de­vel­op­ing a sec­ond-gen­er­a­tion mR­NA vac­cine tech­nol­o­gy that could spur stronger im­mu­ni­ty with small­er dos­es, said its ex­per­i­men­tal ra­bies shots per­formed bet­ter than ex­pect­ed in an 84-per­son clin­i­cal tri­al.

In an ex­clu­sive in­ter­view with End­points News, CEO Nathaniel Wang said his com­pa­ny plans to raise a Se­ries B round based on the ra­bies da­ta. But with­out a phar­ma or gov­ern­ment part­ner, Repli­cate is un­like­ly to ad­vance the ra­bies shot in­to a larg­er study, he added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.